715

(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-A MINE

Created:	2004-08-16
Last modified:	2020-06-05

Find Related PDB Entry
3 entries where 715 is found as a standalone ligand

Find related ligands: Help
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	43
Chiral Atom Count	1
Bond Count	45
Aromatic Bond Count	11

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-A MINE
Synonyms	Sitagliptin
Systematic Name (OpenEye OEToolkits)	(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[3,4-c]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
Formula	C₁₆ H₁₅ F₆ N₅ O
Molecular Weight	407.314
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	10.04	Fc1cc(c(F)cc1F)CC(N)CC(=O)N3Cc2nnc(n2CC3)C(F)(F)F
SMILES	CACTVS	3.341	N[CH](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc3cc(F)c(F)cc3F
SMILES	OpenEye OEToolkits	1.5.0	c1c(c(cc(c1F)F)F)CC(CC(=O)N2CCn3c(nnc3C(F)(F)F)C2)N
Canonical SMILES	CACTVS	3.341	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc3cc(F)c(F)cc3F
Canonical SMILES	OpenEye OEToolkits	1.5.0	c1c(c(cc(c1F)F)F)C[C@H](CC(=O)N2CCn3c(nnc3C(F)(F)F)C2)N
InChI	InChI	1.03	InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
InChIKey	InChI	1.03	MFFMDFFZMYYVKS-SECBINFHSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB01261
Name	Sitagliptin
Groups	investigational approved
Description	Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006[L6061].
Synonyms	Sitagliptin Sitagliptin tartrate hemihydrate Sitagliptin hydrochloride monohydrate Sitagliptin phosphate Sitagliptin malate Sitagliptina Sitagliptine Sitagliptinum Sitagliptin fumarate
Brand Names	Ach-sitagliptin Ag-sitagliptin Hydrochloride / Metformin Auro-sitagliptin Hydrochloride and Metformin Hydrochloride Sitagliptin-metformin Prz-sitagliptin Teva-sitagliptin Malate Apo-sitagliptin Sitagliptin and metformin hydrochloride Ag-sitagliptin Janumet XR Janumet Zituvimet Apo-sitagliptin Malate / Metformin Hydrochloride M-sitagliptin Januvia Sitagliptin Accord Pro-sitagliptin Malate / Metformin Hydrochloride Nb-sitagliptin-metformin Ristaben Riva-sitagliptin Tartrate/metformin Pro-sitagliptin-metformin Steglujan Sandoz Sitagliptin-metformin Mint-sitagliptin Reddy-sitagliptin and Metformin Hydrochloride Sitagliptin/metformin Hydrochloride Accord Sitagliptin Phosphate/Metformin Hydrochloride Juvisync Sandoz Sitagliptin Jamp Sitagliptin Apo-sitagliptin/metformin XR Reddy-sitagliptin Sitagliptin/metformin Hydrochloride Sun Pro-sitagliptin Malate Jamp Sitagliptin Hydrochloride / Metformin Efficib Apo-sitagliptin Malate Sitagliptin and Metformin Hydrochloride Riva Sitagliptin Mint-sitagliptin/metformin Riva Sitagliptin/metformin PMS-sitagliptin-metformin PMS-sitagliptin Tartrate/metformin Nb-sitagliptin Xelevia Nra-sitagliptin Brynovin Bio-sitagliptin Auro-sitagliptin Prz-sitagliptin-metformin Taro-sitagliptin Fumarate Sitagliptin Sun Zituvio Tesavel Apo-sitagliptin-metformin Sitagliptin - Metformin Nat-sitagliptin Teva-sitagliptin Malate / Metformin Zituvimet XR Ristfor Sitagliptin Velmetia Pro-sitagliptin Sandoz Sitagliptin-metformin XR PMS-sitagliptin
Indication	Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.[L41220] It is also used in combination with [metformin] [L41215] or [ertugliflozin].[L41225]
Categories	Agents causing angioedema Alimentary Tract and Metabolism Blood Glucose Lowering Agents Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates DPP-IV Inhibitors Drugs that are Mainly Renally Excreted Drugs Used in Diabetes Enzyme Inhibitors Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Hypoglycemia-Associated Agents Incretins OAT3/SLC22A8 Substrates Oral Hypoglycemics P-glycoprotein substrates Protease Inhibitors Triazoles
ATC-Code	A10BH51 A10BD24 A10BD07 A10BD29 A10BH01 A10BD12
CAS number	486460-32-6

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
Dipeptidyl peptidase 4	MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLK...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	substrate
ATP-dependent translocase ABCB1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
Organic anion transporter 3	MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682